1. RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib 
Sanjay Mukhopadhyay, MD, Nathan A. Pennell, MD, Siraj M. Ali, MD, PhD, Jeffrey S. Ross, MD, Patrick C. Ma, MD, MSc, Vamsidhar Velcheti, MD 
Journal of Thoracic Oncology 
Volume 9, Issue 11, Pages (November 2014)
DOI: /JTO
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Radiologic features and responses to RET inhibitor (cabozantinib) therapy in RET-rearranged lung adenocarcinomas. A–C, case 1. A, Bilateral reticulonodular opacities with solid and cavitary nodules in a lymphangitic distribution. PET-CT at presentation (B) and 1 month after cabozantinib therapy (C), demonstrating decrease in size and FDG avidity of nodules. D–E, case 2. CT scan at presentation (D) and 1 month after cabozantinib therapy (E), showing a decrease in size of the confluent right infrahilar mass and adenopathy involving the central right middle lobe, development of focal cavitation, and improvement in patency of the right middle lobe bronchus.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Histologic features of lung adenocarcinomas with RET rearrangements. A, Case 1. Psammoma bodies within solid-pattern tumor. B, Case 3. Tumor cells and psammoma bodies within a lymphatic. C, Case 4. High-grade nuclei, intranuclear cytoplasmic inclusion (top right), and a psammoma body (top center). D, Case 1. Mucinous cribriform pattern. E, Case 2. Signet-ring cells. Psammoma bodies were also present (not shown). F, Case 4. Large intracytoplasmic vacuoles.
Journal of Thoracic Oncology 2014 9, DOI: ( /JTO )
Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions